Working… Menu

A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01162876
Recruitment Status : Completed
First Posted : July 15, 2010
Last Update Posted : March 9, 2017
Information provided by (Responsible Party):
Kyowa Kirin Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of saxagliptin administered before breakfast for 14 consecutive days in patients with type 2 diabetes mellitus.

Condition or disease Intervention/treatment Phase
Diabetes Drug: saxaglipitin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus
Study Start Date : July 2010
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Saxagliptin

Arm Intervention/treatment
Experimental: saxagliptin
5 mg daily for 14days
Drug: saxaglipitin
oral administration of 5 mg tablet before breakfast for 14 consecutive days

Primary Outcome Measures :
  1. Pharmacokinetics [ Time Frame: daily, up to 42days ]
    Concentrations of plasma saxagliptin and BMS-510849

  2. Pharmacodynamics [ Time Frame: daily, up to 42 days ]
    Plasma DPP4 actyivity Concentrations of blood glucose, C-peptide, insulin and glucagon Plasma active GLP-1 concentration

Secondary Outcome Measures :
  1. Safety issues [ Time Frame: daily, up to 42 days ]
    Adverse events, skin symptom findings, blood pressure and pulse rate, body temperature, body weight, hypoglycemic symptoms, 12-lead ECG, clinical laboratory tests, and pregnancy test (in women of childbearing potential only)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who meet all of the following criteria will be included:

    1. HbA1c level ≥7.0% and < 9.0%
    2. Fasting glucose level ≥130mg/dL and <210mg/dL
    3. Patients who are capable of giving informed consent
    4. Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after completion of the study

Exclusion Criteria:

  • Patients with type 1 diabetes mellitus; patients with diabetes mellitus due to other specified drugs, mechanisms, or diseases; and patients with gestational diabetes mellitus
  • Patients with a medical history of diabetic coma
  • Patients with heart failure
  • Patients with a complication of active chronic hepatitis or hepatic cirrhosis
  • Patients undergoing treatment of glomerular diseases other than diabetic nephropathy
  • Patients with a history or complication of malignant tumor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01162876

Layout table for location information
Kyushu Clinical Pharmacology Reserch Clinic
Fukuoka, Japan
Sponsors and Collaborators
Kyowa Kirin Co., Ltd.
Layout table for additonal information
Responsible Party: Kyowa Kirin Co., Ltd. Identifier: NCT01162876    
Other Study ID Numbers: 262-09-003
JapicCTI-101190 ( Other Identifier: JAPIC )
First Posted: July 15, 2010    Key Record Dates
Last Update Posted: March 9, 2017
Last Verified: March 2017
Keywords provided by Kyowa Kirin Co., Ltd.:
Diabetes, Type 2
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases